Pancreatitis - Pipeline Insight, 2025

DelveInsight’s, “Pancreatitis - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pancreatitis Understanding

Pancreatitis: Overview

Pancreatitis is inflammation of the pancreas that occurs when pancreatic enzyme secretions build up and begin to digest the organ itself. It can occur as acute, painful attacks lasting a matter of days, or it may be a chronic, condition that progresses over a period of years. Acute pancreatitis refers to pancreatitis that develops suddenly, most often as a result of gallstones or alcohol ingestion. Reaction to certain medications, trauma, and infectious causes can also lead to acute pancreatitis. Acute pancreatitis can be life threatening, but most patients recover completely. Chronic pancreatitis refers to ongoing disease in which the pancreas continues to sustain damage and lose function over time. The majority of cases of chronic pancreatitis result from ongoing alcohol abuse, but some cases are hereditary or due to diseases such as cystic fibrosis. Approximately 87,000 people are treated for pancreatitis each year in the U.S., with the disease affecting roughly twice as many males as females. Occurring very rarely in children, pancreatitis primarily affects adults. In more than half of patients, chronic pancreatitis is caused by long-term abuse of alcohol, which leads to damage and scarring of the pancreas. Treatment for acute pancreatitis may include nutritional support with feeding tubes or intravenous (IV) nutrition, antibiotics, and pain medications.

""Pancreatitis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatitis pipeline landscape is provided which includes the disease overview and Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pancreatitis.
• In the coming years, the Pancreatitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Pancreatitis treatment market. Several potential therapies for Pancreatitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pancreatitis market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pancreatitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Pancreatitis Emerging Drugs Chapters

This segment of the Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatitis Emerging Drugs

• Auxora: CalciMedica, Inc.

CalciMedica’s lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor that in animal models and in clinical trials has prevented acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. Auxora is currently being evaluated in multiple ongoing clinical trials: a blinded, placebo-controlled Phase 2b trial in patients with acute pancreatitis with accompanying systemic inflammatory response syndrome (SIRS), a Phase 2 dose-escalation trial in patients with COVID-19 pneumonia and acute respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation, and an investigator-initiated Phase 1/2 trial in pediatric acute lymphocytic leukemia (ALL) patients who develop acute pancreatitis as a result of a specific chemotherapy. Auxora has been evaluated in CARDEA, a 284-patient randomized, placebo-controlled trial in hospitalized COVID-19 pneumonia patients that was Part Two of a Phase 2 study. Results of Part One of the Phase 2 study, a randomized open label trial in 30 critical and severe COVID-19 pneumonia patients, were published in the peer reviewed journal, Critical Care, in August 2020. Results of a randomized open label Phase 2a trial in 21 acute pancreatitis patients with SIRS were published in the peer reviewed journal, Pancreas, in June 2021.

• NI 03: SCM Lifescience

NI 03 is being developed by Kangen Pharmaceuticals for the treatment of chronic pancreatitis. Phase I/II development is underway in the US.

• RABI-767: Lamassu Pharma, LLC

Lamassu’s lead candidate, RABI-767 is a novel small molecule therapy for acute pancreatitis. It was developed at Mayo Clinic by leading scientists, and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. Lamassu is currently focused on continued development of this compound through safety testing in preparation for definitive clinical trials with the ultimate goal of saving the lives of patients afflicted with this disease.

Further product details are provided in the report……..

Pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pancreatitis

There are approx. 10+ key companies which are developing the therapies for Pancreatitis. The companies which have their Pancreatitis drug candidates in the most advanced stage, i.e. phase II include, CalciMedica, Inc.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatitis drugs.

Pancreatitis Report Insights

• Pancreatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatitis drugs?
• How many Pancreatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CalciMedica, Inc.
• SCM Lifescience
• Lamassu Pharma, LLC
• SCM Lifescience Co., LTD.
• AzurRx SAS
• Kynos Therapeutics
• D&D Pharmatech.
• JD BIOSCIENCE INC.
• Regeneron Pharmaceuticals
• Cypralis Limited

Key Products

• Auxora
• NI 03
• RABI-767
• SCM-AGH
• MS1819-SD
• Research programme: KMO inhibitors
• CM 6018
• TLY012
• EVINACUMAB
• CC 4066

Show more